M. Eileen Dolan

14.8k total citations · 1 hit paper
220 papers, 10.5k citations indexed

About

M. Eileen Dolan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, M. Eileen Dolan has authored 220 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Molecular Biology, 62 papers in Oncology and 54 papers in Cancer Research. Recurrent topics in M. Eileen Dolan's work include DNA Repair Mechanisms (66 papers), Epigenetics and DNA Methylation (31 papers) and Carcinogens and Genotoxicity Assessment (26 papers). M. Eileen Dolan is often cited by papers focused on DNA Repair Mechanisms (66 papers), Epigenetics and DNA Methylation (31 papers) and Carcinogens and Genotoxicity Assessment (26 papers). M. Eileen Dolan collaborates with scholars based in United States, Canada and United Kingdom. M. Eileen Dolan's co-authors include Anthony E. Pegg, Nancy J. Cox, Shiwei Duan, Eric R. Gamazon, Robert C. Moschel, Wei Zhang, Dan L. Nicolae, R C Moschel, R. Stephanie Huang and Mark J. Ratain and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

M. Eileen Dolan

216 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS

2010 874 citations Eric R. Gamazon, Shiwei Duan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Eileen Dolan United States	53	6.5k	2.8k	2.3k	1.7k	1.3k	220	10.5k
Jennifer A. Chan United States	47	5.8k 0.9×	2.8k 1.0×	3.2k 1.4×	739 0.4×	1.1k 0.9×	124	11.3k
Marcel Kool Germany	51	8.2k 1.3×	5.5k 2.0×	1.7k 0.7×	1.2k 0.7×	3.6k 2.9×	215	14.4k
Kenneth V. Honn United States	63	5.0k 0.8×	2.9k 1.1×	3.4k 1.4×	1.4k 0.8×	466 0.4×	243	12.8k
Kenneth H. Cowan United States	61	7.6k 1.2×	6.1k 2.2×	1.9k 0.8×	2.1k 1.2×	380 0.3×	195	13.4k
Clifford J. Steer United States	66	8.1k 1.2×	2.4k 0.9×	2.9k 1.2×	1.0k 0.6×	363 0.3×	276	13.6k
Qing Li China	52	6.1k 0.9×	2.1k 0.8×	1.9k 0.8×	677 0.4×	711 0.6×	300	10.2k
Ji Luo United States	43	12.1k 1.9×	4.2k 1.5×	2.7k 1.2×	880 0.5×	811 0.6×	99	16.0k
Robert Roskoski United States	57	9.9k 1.5×	4.1k 1.5×	1.4k 0.6×	616 0.4×	1.1k 0.9×	173	16.3k
Ingrid Herr Germany	50	6.6k 1.0×	3.0k 1.1×	2.1k 0.9×	616 0.4×	477 0.4×	139	10.2k
Linda S. Steelman United States	49	7.5k 1.2×	3.3k 1.2×	1.9k 0.8×	495 0.3×	682 0.5×	112	11.2k

Countries citing papers authored by M. Eileen Dolan

Since Specialization

Citations

This map shows the geographic impact of M. Eileen Dolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Eileen Dolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Eileen Dolan more than expected).

Fields of papers citing papers by M. Eileen Dolan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Eileen Dolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Eileen Dolan. The network helps show where M. Eileen Dolan may publish in the future.

Co-authorship network of co-authors of M. Eileen Dolan

This figure shows the co-authorship network connecting the top 25 collaborators of M. Eileen Dolan. A scholar is included among the top collaborators of M. Eileen Dolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Eileen Dolan. M. Eileen Dolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sanchez, Victoria A., Megan M. Shuey, Paul C. Dinh, et al.. (2023). Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy. Journal of Clinical Oncology. 41(12). 2211–2226. 23 indexed citations

Dinh, Paul C., Patrick O. Monahan, Sophie D. Fosså, et al.. (2023). Impact of pain and adverse health outcomes on long-term US testicular cancer survivors. JNCI Journal of the National Cancer Institute. 116(3). 455–467. 7 indexed citations

Trendowski, Matthew R., Emma Wilkinson, Paul C. Dinh, et al.. (2022). Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine. 11(14). 2801–2816. 11 indexed citations

Trendowski, Matthew R., Yadav Sapkota, Lois B. Travis, et al.. (2021). Clinical and genetic risk factors for radiation‐associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 127(21). 4091–4102. 7 indexed citations

Phillips, Christine L., Adam Lane, Robert B. Gerbing, et al.. (2020). Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clinical Cancer Research. 26(12). 2891–2897. 4 indexed citations

Trendowski, Matthew R., Heather E. Wheeler, Darren R. Feldman, et al.. (2020). Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research. 26(24). 6550–6558. 9 indexed citations

Trendowski, Matthew R., et al.. (2018). Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clinical Cancer Research. 25(4). 1147–1155. 88 indexed citations

Gamazon, Eric R., Matthew R. Trendowski, Yujia Wen, et al.. (2018). Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Scientific Reports. 8(1). 733–733. 12 indexed citations

Dolan, M. Eileen, Heather E. Wheeler, Eric R. Gamazon, et al.. (2017). Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clinical Cancer Research. 23(19). 5757–5768. 63 indexed citations

10.

Komatsu, Masaaki, Heather E. Wheeler, Suyoun Chung, et al.. (2015). Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clinical Cancer Research. 21(19). 4337–4346. 36 indexed citations

11.

Morrison, Gladys, Cong Liu, Claudia Wing, et al.. (2015). Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Research. 16(1). 140–148. 10 indexed citations

12.

Calinski, Diane, Haoming Zhang, Susan M. Ludeman, M. Eileen Dolan, & Paul F. Hollenberg. (2015). Hydroxylation and N-Dechloroethylation of Ifosfamide and Deuterated Ifosfamide by the Human Cytochrome P450s and Their Commonly Occurring Polymorphisms. Drug Metabolism and Disposition. 43(7). 1084–1090. 17 indexed citations

13.

Leandro‐García, Luis J., Susanna Leskelä, Carlos Jara, et al.. (2012). Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research. 18(16). 4441–4448. 57 indexed citations

14.

Wheeler, Heather E., Lidija K. Gorsic, Marleen M. Welsh, et al.. (2011). Genome-Wide Local Ancestry Approach Identifies Genes and Variants Associated with Chemotherapeutic Susceptibility in African Americans. PLoS ONE. 6(7). e21920–e21920. 19 indexed citations

15.

Horton, Terzah M., Debananda Pati, Linna Zhang, et al.. (2009). Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O 6-methylguanine-DNA methyltransferase activity. Molecular Cancer Therapeutics. 8(8). 2232–2242. 67 indexed citations

16.

Huang, R. Stephanie, Shiwei Duan, Emily O. Kistner, Christine Hartford, & M. Eileen Dolan. (2008). Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Molecular Cancer Therapeutics. 7(9). 3038–3046. 49 indexed citations

17.

Odenike, Olatoyosi, Richard A. Larson, Devika Gajria, et al.. (2008). Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational New Drugs. 26(3). 233–239. 44 indexed citations

18.

Hu, Ya Jun, M. Eileen Dolan, Herman Yee, et al.. (2004). Allelic Loss at the GPx-1 Locus in Cancer of the Head and Neck. Biological Trace Element Research. 101(2). 97–106. 35 indexed citations

19.

Johnston, Patrick G., K A Behan, C J Allegra, et al.. (1997). Thymidylate Synthase Expression and Response to Neoadjuvant Chemotherapy in Patients With Advanced Head and Neck Cancer. JNCI Journal of the National Cancer Institute. 89(4). 308–313. 64 indexed citations

20.

Vokes, Everett E., Rosemarie Mick, M.S. Kies, et al.. (1996). Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.. Journal of Clinical Oncology. 14(5). 1663–1671. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact